Company Page - DYNAVAX TECHNOLOGIES CORP

2929 Seventh Street, Suite 100	Research Report	Earnings Snapshot - Last 11/05/18
Berkeley, CA 94710	Fact Sheet
Phone: (510) 848-5100	Financial Statements
	Peer Comparison
	Annual Reports

Dino Dina, CEO, Robert L. Coffman, CSO, Deborah A. Smeltzer, CFO
A biopharmaceutical company focused on discovering, developing and commercializing innovative products to treat and prevent allergies, infectious diseases, cancer and chronic inflammatory diseases. IPO at $7.50 February 18, 2004. Raised $45 million, selling 6 million shares, 25% of the outstanding. Lead Manager: Bear Stearns. Secondary sold 5 million shares at $6.25 October 11, 2005, raising $31 million. Secondary sold 6.2 million shares at $4.40 October 4, 2006, raising $27 million. Positive trial results data for hepatitis B vaccine, Heplisav, reported November 29, 2006. Negative results on hepatitis B vaccine Heplisav Nov 15, 2012.

Historical Charts Technical Analysis

No Historical Data available for DVAX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)

Common DVAX $4.25 $4.25 0 .0 $3.95 $4.25 1,894,936 $3.95 $4.25 87,599,440

Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121

Common Stock $372,297,620

QUICK NAVIGATION			SITE SEARCH Enter Keyword:

Home Subscribe Browser Help Subscriber Services B-to-B Banks Brokerage Telco Site Map Legal Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex